BBOT Insider Trading

Insider Ownership Percentage: 24.40%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $184.86

BridgeBio Oncology Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at BridgeBio Oncology Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BridgeBio Oncology Therapeutics Share Price & Price History

Current Price: $1.94
Price Change: ▼ Price Decrease of -0.04 (-2.02%)
As of 11/17/2026 04:00 PM ET

This chart shows the closing price history over time for BBOT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

BridgeBio Oncology Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/13/2026Marc CoboInsiderSell78$2.37$184.8613,734View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for BridgeBio Oncology Therapeutics (NASDAQ:BBOT)

54.89% of BridgeBio Oncology Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at BBOT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

BridgeBio Oncology Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/17/2026Goldman Sachs Group Inc.239,614$0.98M0.0%+134.7%0.299%Search for SEC Filing on Google Icon
11/15/2026Jump Financial LLC26,775$0.11M0.0%-56.8%0.033%Search for SEC Filing on Google Icon
11/14/2026Marshall Wace LLP482,935$1.98M0.0%N/A0.602%Search for SEC Filing on Google Icon
11/13/2026Palumbo Wealth Management LLC95,443$0.39M0.1%+11.5%0.119%Search for SEC Filing on Google Icon
11/12/2026State Street Corp893,262$3.66M0.0%-56.9%1.114%Search for SEC Filing on Google Icon
10/28/2026China Universal Asset Management Co. Ltd.16,000$63K0.0%N/A0.020%Search for SEC Filing on Google Icon
10/27/2026Regents of The University of California2,509,446$10.29M0.2%N/A3.130%Search for SEC Filing on Google Icon
9/9/2026Opaleye Management Inc.700,000$5.33M0.5%+1,213.8%0.873%Search for SEC Filing on Google Icon
9/9/2026Tidal Investments LLC93,339$0.71M0.0%+13.6%0.116%Search for SEC Filing on Google Icon
9/9/2026Squarepoint Ops LLC19,662$0.15M0.0%-54.5%0.025%Search for SEC Filing on Google Icon
8/21/2026AXQ Capital LP10,728$82K0.0%-38.2%0.013%Search for SEC Filing on Google Icon
8/19/2026Wellington Management Group LLP2,789,302$21.25M0.0%-1.0%3.479%Search for SEC Filing on Google Icon
7/10/2026Tema ETFs LLC93,339$0.71M0.0%+13.6%0.117%Search for SEC Filing on Google Icon
5/28/2026Avidity Partners Management LP43,853$0.39M0.1%N/A0.055%Search for SEC Filing on Google Icon
5/16/2026The Manufacturers Life Insurance Company35,692$0.32M0.0%-34.1%0.045%Search for SEC Filing on Google Icon
5/15/2026Octagon Capital Advisors LP719,000$6.44M0.7%-31.1%0.897%Search for SEC Filing on Google Icon
5/15/2026Granahan Investment Management LLC231,040$2.07M0.1%N/A0.288%Search for SEC Filing on Google Icon
5/14/2026Renaissance Technologies LLC101,900$0.91M0.0%+37.1%0.127%Search for SEC Filing on Google Icon
2/18/2026XTX Topco Ltd28,633$0.36M0.0%+22.4%0.036%Search for SEC Filing on Google Icon
2/18/2026Ikarian Capital LLC220,231$2.76M0.2%-10.2%0.275%Search for SEC Filing on Google Icon
2/18/2026Wellington Management Group LLP2,907,003$36.40M0.0%-1.8%3.634%Search for SEC Filing on Google Icon
2/18/2026Quadrature Capital Ltd12,922$0.16M0.0%N/A0.016%Search for SEC Filing on Google Icon
2/18/2026Millennium Management LLC241,415$3.02M0.0%-34.7%0.302%Search for SEC Filing on Google Icon
2/18/2026Catalio Capital Management LP410,700$5.14M1.0%N/A0.513%Search for SEC Filing on Google Icon
2/18/2026Boothbay Fund Management LLC67,034$0.84M0.0%-30.6%0.084%Search for SEC Filing on Google Icon
2/18/2026Armistice Capital LLC1,000,000$12.52M0.1%+142.7%1.250%Search for SEC Filing on Google Icon
2/17/2026ADAR1 Capital Management LLC226,248$2.83M0.2%-54.9%0.283%Search for SEC Filing on Google Icon
2/17/2026Paradigm Biocapital Advisors LP2,261,749$28.32M0.7%+21.2%2.828%Search for SEC Filing on Google Icon
2/17/2026Laurion Capital Management LP1,464,938$18.34M0.7%+40.1%1.831%Search for SEC Filing on Google Icon
2/17/2026Price T Rowe Associates Inc. MD803,134$10.06M0.0%-9.3%1.004%Search for SEC Filing on Google Icon
2/17/2026Adage Capital Partners GP L.L.C.1,400,000$17.53M0.0%-5.9%1.750%Search for SEC Filing on Google Icon
2/17/2026Persistent Asset Partners Ltd8,585$0.11M0.0%N/A0.011%Search for SEC Filing on Google Icon
2/16/2026Squarepoint Ops LLC11,515$0.14M0.0%N/A0.014%Search for SEC Filing on Google Icon
2/13/2026The Manufacturers Life Insurance Company 54,192$0.67M0.0%N/A0.068%Search for SEC Filing on Google Icon
2/13/2026State Street Corp218,278$2.73M0.0%+23.5%0.273%Search for SEC Filing on Google Icon
2/12/2026Renaissance Technologies LLC74,300$0.93M0.0%N/A0.093%Search for SEC Filing on Google Icon
2/12/2026CIBC Private Wealth Group LLC5,000$63K0.0%N/A0.006%Search for SEC Filing on Google Icon
2/11/2026BIT Capital GmbH25,000$0.31M0.0%N/A0.031%Search for SEC Filing on Google Icon
2/10/2026TD Asset Management Inc117,150$1.47M0.0%-9.9%0.146%Search for SEC Filing on Google Icon
2/10/2026Goldman Sachs Group Inc.94,651$1.19M0.0%N/A0.118%Search for SEC Filing on Google Icon
2/9/2026Geode Capital Management LLC561,987$7.04M0.0%+3.8%0.703%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
BridgeBio Oncology Therapeutics logo
We are a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Throughout this prospectus, we will refer to this as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any potential business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business or industry, we intend to focus on healthcare or healthcare related industries, which can benefit from the expertise and capabilities of our management team in order to create long-term shareholder value. Our sponsor is an affiliate of Cormorant, a leading life sciences focused investment firm with over $2 billion in assets under management as of December 31, 2022. Our Chairperson and Chief Executive Officer, Bihua Chen, founded Cormorant and is the managing member of Cormorant. Since its inception in 2013, Cormorant has focused on the healthcare industry and invests, throughout their growth cycle, in companies that discover and develop therapeutic drugs or medical technology. Cormorant is an active life-science investor with investments in over 100 privately held, life science-focused companies over this period. Of these investments, over 50 have completed initial public offerings. Notable successes include Prometheus Biosciences, Inc., Turning Point Therapeutics, Inc., and MyoKardia, Inc., each of which has been acquired for more than $4 billion. Other notable successes include BridgeBio Pharma Inc. and Apellis Pharmaceuticals Inc., each of which is a public company with a market capitalization greater than $1 billion. Our executive offices are located at 200 Clarendon Street, 52nd Floor, Boston, MA.
Read More on BridgeBio Oncology Therapeutics

Today's Range

Now: $1.94
Low: $1.92
High: $2.09

50 Day Range

MA: $3.51
Low: $1.98
High: $8.86

52 Week Range

Now: $1.94
Low: $1.92
High: $14.87

Volume

374,900 shs

Average Volume

435,581 shs

Market Capitalization

$155.69 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Who are the company insiders with the largest holdings of BridgeBio Oncology Therapeutics?

BridgeBio Oncology Therapeutics' top insider investors include:
  1. Andrew Kai Kang (President)
  2. Marc Cobo (Insider)
Learn More about top insider investors at BridgeBio Oncology Therapeutics.

Who are the major institutional investors of BridgeBio Oncology Therapeutics?

BridgeBio Oncology Therapeutics' top institutional investors include:
  1. Regents of The University of California — 3.13%
  2. State Street Corp — 1.11%
  3. Marshall Wace LLP — 0.60%
  4. Goldman Sachs Group Inc. — 0.30%
  5. Palumbo Wealth Management LLC — 0.12%
  6. Jump Financial LLC — 0.03%
Learn More about top institutional investors of BridgeBio Oncology Therapeutics stock.

Which institutional investors are selling BridgeBio Oncology Therapeutics stock?

In the previous quarter, BBOT stock was sold by these institutional investors:
  1. State Street Corp
  2. Jump Financial LLC

Which institutional investors are buying BridgeBio Oncology Therapeutics stock?

Within the last quarter, BBOT stock was bought by institutional investors including:
  1. Regents of The University of California
  2. Marshall Wace LLP
  3. Goldman Sachs Group Inc.
  4. China Universal Asset Management Co. Ltd.
  5. Palumbo Wealth Management LLC